TargetRx Atlas

MRNA basic information

  • mRNA ID:ENST00000563924
  • Gene Name:CD31
  • mRNA database:Ensembl
  • mRNA expression :down-regulated
  • mRNA Method:RT-PCR
  • mRNA Pathway:VEGFR2/ERK pathway
  • Evidence:validated
  • (mRNA-drug)

Drug basic information

  • Drug ID:DB04115 (EXPT00672)
  • Drug Name:Berberine
  • Drug Method:down-regulated the gene expression the gene expression

Disease basic infommation

  • Disease:glioblastoma
  • Tissue:cell lines ( U87,U251)

Other information

  • Title:Berberine inhibits angiogenesis in glioblastoma xenografts by targeting the VEGFR2/ERK pathway
  • Journal:Pharm Biol
  • Published:2018
  • PubMed ID:31070539
  • Abstract:Context:Berberine is used in traditional Chinese medicine for thousands of years with recent reports of its anticancer activity. Objective:To test antiangiogenic effects of berberine on human glioblastoma and clarify involvement of the VEGFR2/ERK pathway. Materials and methods:Cell viability, proliferation and migration assays were performed to determine in vitro antiangiogenic effects of berberine (6.25-200 μmol/L, 6-48 h). Ectopic and orthotopic xenograft models in BALB/c nude mice were induced to determine antitumour and antiangiogenic effects of berberine (50 mg/kg by oral gavage for 28 days) or vehicle control (carboxymethylcellulose sodium). Results:Berberine inhibited cell viability (IC50of 42 and 32 μmol/L, respectively) and proliferation of U87 and U251 human glioblastoma cell lines. Berberine (50 μmol/L) inhibited cell migration of HUVEC by 67.50 ± 8.14% in the Transwell assay and tube formation of HUVEC by 73.00 ± 11.12% in the Matrigel assay. In the ectopic xenograft model, tumour weight was significantly decreased by 50 mg/kg of berberine (401.2 ± 71.5 mg vs. 860.7 ± 117.1 mg in vehicle group, p ? 0.001). Berberine significantly decreased haemoglobin content (28.81 ± 3.64 μg/mg vs. 40.84 ± 5.15 μg/mg in vehicle group, p ? 0.001) and CD31 mRNA expression in tumour tissue. In the orthotopic xenograft model, berberine (50 mg/kg) significantly improved the survival rate of mice (p = 0.0078). Berberine inhibited (p ? 0.001) the phosphorylation of VEGFR2 and ERK. Discussion and conclusions:Berberine inhibited angiogenesis in glioblastoma xenografts by targeting the VEGFR2/ERK pathway. Our work sheds new light on complementary and alternative therapy for glioblastoma.
@Copyright Harbin Medical University
　The 2nd Affiliated Hospital of Harbin Medical University
　 备案号：鲁ICP备2022025566号-3